AR and neoplasm: In particular, basal-like immune suppressive (BLIS), mesenchymal (MES), and luminal androgen receptor (LAR) subtypes showed lower levels of tumor infiltrating lymphocytes and suppressive immune signatures, which contribute to their reduced responsiveness to immunotherapy [10].